Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J, Redondo A, Santaballa A, Garrigos L, Rubio MJ, Lainez N, González MI, Cueva JF, Barquin A, Grazioso TP, Hurtado A, Sevillano E, Grande E, Rodriguez-Moreno JF, Navarro P. García-Donas J, et al. Among authors: sevillano e. Gynecol Oncol. 2024 Dec;191:233-239. doi: 10.1016/j.ygyno.2024.10.019. Epub 2024 Oct 24. Gynecol Oncol. 2024. PMID: 39454227 Clinical Trial.
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).
Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Barquin A, Grande E, Alia EG, Sevillano E, Bover I, Grazioso TP, Sanchez-Escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF. Garcia-Donas J, et al. Among authors: sevillano e. Clin Transl Oncol. 2024 Dec 30. doi: 10.1007/s12094-024-03827-4. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39738931
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM. Ruíz-Borrego M, et al. Among authors: sevillano e. Breast Cancer Res Treat. 2019 Aug;177(1):115-125. doi: 10.1007/s10549-019-05296-8. Epub 2019 May 31. Breast Cancer Res Treat. 2019. PMID: 31152327 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castañón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Peña F. Carmona-Bayonas A, et al. Among authors: sevillano e. J Clin Oncol. 2015 Feb 10;33(5):465-71. doi: 10.1200/JCO.2014.57.2347. Epub 2015 Jan 5. J Clin Oncol. 2015. PMID: 25559804
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.
Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez-Garcia J, Hernando J, Espinosa J, de Castro EM, Ghanem I, Beato C, Blasco A, Garrido M, Mondéjar R, Arcusa MÁ, Aragón I, Manzano A, Sevillano E, Castañón E, Ayala F; Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM). Carmona-Bayonas A, et al. Among authors: sevillano e. Clin Transl Oncol. 2017 Mar;19(3):386-395. doi: 10.1007/s12094-016-1540-y. Epub 2016 Aug 15. Clin Transl Oncol. 2017. PMID: 27525978
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia.
Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, Font C, Biosca M, Blasco A, Lozano R, Ramchandani A, Beato C, de Castro EM, Espinosa J, Martínez-García J, Ghanem I, Cubero JH, Manrique IA, Navalón FG, Sevillano E, Manzano A, Virizuela J, Garrido M, Mondéjar R, Arcusa MÁ, Bonilla Y, Pérez Q, Gallardo E, Del Carmen Soriano M, Cardona M, Lasheras FS, Cruz JJ, Ayala F. Fonseca PJ, et al. Among authors: sevillano e. Br J Cancer. 2016 May 24;114(11):1191-8. doi: 10.1038/bjc.2016.118. Epub 2016 May 17. Br J Cancer. 2016. PMID: 27187687 Free PMC article.
42 results